Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder

被引:36
|
作者
Eriksson, Elias [1 ]
Ekman, Agneta [1 ]
Sinclair, Suzanne [2 ]
Sorvik, Karin [3 ]
Ysander, Christina [4 ]
Mattson, Ulla-Britt [4 ]
Nissbrandt, Hans [1 ]
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Pharmacol, Gothenburg, Sweden
[2] Lakarhuset, Gothenburg, Sweden
[3] Kungalv Hosp, Gothenburg, Sweden
[4] Univ Gothenburg, Inst Clin Neurosci, Gothenburg, Sweden
关键词
D O I
10.1097/JCP.0b013e3181678a28
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This is the first placebo-controlled trial evaluating the efficacy of the selective serotonin reuptake inhibitor (SSRI), escitalopram, in the treatment of premenstrual dysphoric disorder (PMDD). Women with PMDD (intention-to-treat population, n = 151) were treated intermittently for 3 months, during luteal phases only, with 10 mg/d escitalopram, 20 mg/d escitalopram, or placebo. Escitalopram was found to exert a marked and a dose-dependent symptom-reducing effect, 20 mg/d being clearly superior to 10 mg/d. Although the primary outcome parameter, that is, the sum of the symptoms irritability, depressed mood, tension, and affective lability, was decreased by 90% with 20 mg/d escitalopram, the effect of active treatment on breast tenderness, food craving, and lack of energy was more modest and not significantly different from that of placebo; this outcome supports our previous assumption that the former symptoms are more inclined to respond to intermittent administration of an SSRI than are the latter. Although the placebo response was high, the difference between the placebo group and the 20-mg/d escitalopram group with respect to the percentage of subjects displaying 80% or greater reduction in the rating of the cardinal symptom of PMDD, that is, irritability, was considerable: 30% versus 80%. Adverse events were those normally reported in SSRI trials, such as nausea and reduced libido, and were not more common in patients given 20 mg/d of escitalopram than in patients given the lower dose. This study supports the usefulness of escitalopram for the treatment of PMDD and sheds further light on how different components of this syndrome are differently influenced by intermittent administration of an SSRI.
引用
收藏
页码:195 / 202
页数:8
相关论文
共 50 条
  • [1] A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder
    Freeman, EW
    Sondheimer, SJ
    Sammel, MD
    Ferdousi, T
    Lin, H
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (06) : 769 - 773
  • [2] Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline
    Halbreich, U
    Kahn, LS
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (11) : 2065 - 2078
  • [3] Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder
    Freeman, EW
    CNS DRUGS, 2004, 18 (07) : 453 - 468
  • [4] Luteal Phase Administration of Agents for the Treatment of Premenstrual Dysphoric Disorder
    Ellen W. Freeman
    CNS Drugs, 2004, 18 : 453 - 468
  • [5] Luteal phase vs. symptom-onset dosing with escitalopram for premenstrual dysphoric disorder: A preliminary study
    Freeman, EW
    Sondheimer, SJ
    Sammel, MD
    Ferousi, T
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S170 - S171
  • [6] Intermittent, luteal phase nefazodone treatment of premenstrual dysphoric disorder
    Kodesh, A
    Katz, S
    Lerner, AG
    Finkel, B
    Sigal, M
    JOURNAL OF PSYCHOPHARMACOLOGY, 2001, 15 (01) : 58 - 60
  • [7] Luteal phase treatment of fluoxetine in premenstrual dysphoric disorder (PMDD): Effect on sexual functioning
    Kornstein, S
    Miner, C
    JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 2001, 10 (04): : 398 - 398
  • [8] LATE LUTEAL PHASE DYSPHORIC DISORDER (PREMENSTRUAL SYNDROMES) - CLINICAL IMPLICATIONS
    BLUMENTHAL, SJ
    NADELSON, CC
    JOURNAL OF CLINICAL PSYCHIATRY, 1988, 49 (12) : 469 - 474
  • [9] Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder
    Halbreich, U
    Bergeron, R
    Yonkers, KA
    Freeman, E
    Stout, AL
    Cohen, L
    OBSTETRICS AND GYNECOLOGY, 2002, 100 (06): : 1219 - 1229
  • [10] Dysregulated Luteal Phase Startle Response in Premenstrual Dysphoric Disorder is Corrected by Luteal Sertraline Treatment
    Hantsoo, Lisa
    Grillon, Christian
    Epperson, C. Neill
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S320 - S321